Policies and Practices Regarding Grants of Equity Awards

Our Compensation Committee and Board generally make equity grants on regularly scheduled dates. Our Board or Compensation Committee may change any regularly scheduled grant date if our Board or Compensation Committee determines that making grants on such date would not be in the Company’s best interest. Equity grants may also be made on other dates in connection with new hires, promotions or similar events. During 2025, our Compensation Committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards, and we did not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. As required by Item 402(x) of Regulation S-K under the Exchange Act, we are providing the following information regarding stock options granted to Dr. Musunuri, Dr. Upadhyay, Mr. Ramachandran, and Dr. Qamar on January 2, 2025, one business day before we filed a Current Report on Form 8-K reporting the receipt of a bid price deficiency letter from Nasdaq.


Name	Grant date	Number of securities underlying the award	Exercise price of the award ($/Sh)	Grant date fair value of the award	Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information
Shankar Musunuri, Ph.D., MBA	01/02/25	1,827,485	$0.90	$ 1,385,871	0%
Arun Upadhyay, Ph.D.	01/02/25	730,994	$0.90	$554,500	0%
Ramesh Ramachandran, CPA, MBA, CMA	01/02/25	350,146	$0.90	$266,708	0%
Huma Qamar, M.D., MPH, CMI	01/02/25	1,145,468	$0.90	$868,975	0%

Award Timing Predetermined

true

Award Timing, How MNPI Considered

During 2025, our Compensation Committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards, and we did not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.

Awards Close in Time to MNPI Disclosures, Table

As required by Item 402(x) of Regulation S-K under the Exchange Act, we are providing the following information regarding stock options granted to Dr. Musunuri, Dr. Upadhyay, Mr. Ramachandran, and Dr. Qamar on January 2, 2025, one business day before we filed a Current Report on Form 8-K reporting the receipt of a bid price deficiency letter from Nasdaq.


Name	Grant date	Number of securities underlying the award	Exercise price of the award ($/Sh)	Grant date fair value of the award	Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information
Shankar Musunuri, Ph.D., MBA	01/02/25	1,827,485	$0.90	$ 1,385,871	0%
Arun Upadhyay, Ph.D.	01/02/25	730,994	$0.90	$554,500	0%
Ramesh Ramachandran, CPA, MBA, CMA	01/02/25	350,146	$0.90	$266,708	0%
Huma Qamar, M.D., MPH, CMI	01/02/25	1,145,468	$0.90	$868,975	0%